Serine Deamination Is a New Acid Tolerance Mechanism Observed in Uropathogenic Escherichia coli.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
20 12 2022
Historique:
entrez: 5 12 2022
pubmed: 6 12 2022
medline: 3 3 2023
Statut: ppublish

Résumé

Escherichia coli associates with humans early in life and can occupy several body niches either as a commensal in the gut and vagina, or as a pathogen in the urinary tract. As such, E. coli has an arsenal of acid response mechanisms that allow it to withstand the different levels of acid stress encountered within and outside the host. Here, we report the discovery of an additional acid response mechanism that involves the deamination of l-serine to pyruvate by the conserved l-serine deaminases SdaA and SdaB. l-serine is the first amino acid to be imported in E. coli during growth in laboratory media. However, there remains a lack in knowledge as to how l-serine is utilized. Using a uropathogenic strain of E. coli, UTI89, we show that in acidified media, l-serine is brought into the cell via the SdaC transporter. We further demonstrate that deletion of the l-serine deaminases SdaA and SdaB renders E. coli susceptible to acid stress, similar to other acid stress deletion mutants. The pyruvate produced by l-serine deamination activates the pyruvate sensor BtsS, which in concert with the noncognate response regulator YpdB upregulates the putative transporter YhjX. Based on these observations, we propose that l-serine deamination constitutes another acid response mechanism in E. coli.

Identifiants

pubmed: 36468870
doi: 10.1128/mbio.02963-22
pmc: PMC9765748
doi:

Substances chimiques

Escherichia coli Proteins 0
L-Serine Dehydratase EC 4.3.1.17
Membrane Transport Proteins 0
Pyruvic Acid 8558G7RUTR
Serine 452VLY9402

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0296322

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI168468
Pays : United States

Références

BMC Microbiol. 2008 Feb 26;8:37
pubmed: 18302792
J Biol Chem. 2004 Jul 30;279(31):32418-25
pubmed: 15155761
Nat Rev Microbiol. 2004 Nov;2(11):898-907
pubmed: 15494746
Oral Microbiol Immunol. 1997 Dec;12(6):323-8
pubmed: 9573805
J Bacteriol. 2010 Oct;192(20):5515-25
pubmed: 20729359
BMC Microbiol. 2019 Jan 14;19(1):13
pubmed: 30642259
Am Fam Physician. 2005 Mar 15;71(6):1153-62
pubmed: 15791892
J Pharmacol Exp Ther. 2019 Feb;368(2):157-168
pubmed: 30413628
J Bacteriol. 1981 May;146(2):647-55
pubmed: 6783624
J Bacteriol. 1995 Jul;177(14):4097-104
pubmed: 7608084
J Bacteriol. 2005 Jan;187(1):304-19
pubmed: 15601715
Nat Commun. 2019 Aug 13;10(1):3643
pubmed: 31409795
J Bacteriol. 2004 Sep;186(18):6032-41
pubmed: 15342572
Science. 2006 Dec 8;314(5805):1607-9
pubmed: 17158330
BMC Mol Biol. 2003 Dec 13;4:11
pubmed: 14672541
Int J Mol Sci. 2020 Nov 28;21(23):
pubmed: 33260635
Annu Rev Microbiol. 2013;67:65-81
pubmed: 23701194
J Bacteriol. 2013 Feb;195(4):807-15
pubmed: 23222720
J Bacteriol. 2003 Oct;185(20):6016-24
pubmed: 14526012
FEMS Microbiol Rev. 2012 May;36(3):616-48
pubmed: 22404313
J Bacteriol. 1985 Jun;162(3):1270-5
pubmed: 3888962
Biotechnol Bioeng. 2009 Feb 15;102(3):923-34
pubmed: 18853410
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5977-82
pubmed: 16585510
Sci Rep. 2017 May 3;7(1):1388
pubmed: 28469239
J Bacteriol. 2012 Aug;194(16):4272-84
pubmed: 22685278
J Bacteriol. 1991 Apr;173(8):2473-80
pubmed: 2013569
Nature. 2017 Jun 22;546(7659):528-532
pubmed: 28614296
Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19884-9
pubmed: 17172451
Gastroenterology. 2002 Jul;123(1):187-95
pubmed: 12105847
J Appl Microbiol. 2007 Feb;102(2):352-62
pubmed: 17241340
Cell Res. 2013 May;23(5):635-44
pubmed: 23337585
Eur J Biochem. 1993 Mar 15;212(3):777-84
pubmed: 8385012
FEMS Microbiol Rev. 2014 Nov;38(6):1091-125
pubmed: 24898062
Infect Immun. 2001 Jul;69(7):4572-9
pubmed: 11402001
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Appl Environ Microbiol. 1996 Sep;62(9):3094-100
pubmed: 8795195
Sci Rep. 2022 Jan 11;12(1):486
pubmed: 35017565
Mol Microbiol. 2008 Aug;69(4):870-81
pubmed: 18532981
Appl Environ Microbiol. 2004 Aug;70(8):4792-9
pubmed: 15294816
Nat Rev Urol. 2010 Dec;7(12):653-60
pubmed: 21139641
J Membr Biol. 2018 Feb;251(1):65-74
pubmed: 29374286
J Urol. 1997 Mar;157(3):1127-9
pubmed: 9072556
Front Microbiol. 2018 Nov 15;9:2869
pubmed: 30498489
Adv Appl Microbiol. 2015;92:49-88
pubmed: 26003933

Auteurs

Michelle A Wiebe (MA)

Vanderbilt University, Nashville, Tennessee, USA.

John R Brannon (JR)

Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Bradley D Steiner (BD)

Vanderbilt University, Nashville, Tennessee, USA.

Adebisi Bamidele (A)

Vanderbilt University, Nashville, Tennessee, USA.

Alexandra C Schrimpe-Rutledge (AC)

Vanderbilt University, Nashville, Tennessee, USA.
Center for Innovative Technologies, Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.

Simona G Codreanu (SG)

Vanderbilt University, Nashville, Tennessee, USA.
Center for Innovative Technologies, Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.

Stacy D Sherrod (SD)

Vanderbilt University, Nashville, Tennessee, USA.
Center for Innovative Technologies, Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.

John A McLean (JA)

Vanderbilt University, Nashville, Tennessee, USA.
Center for Innovative Technologies, Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.

Maria Hadjifrangiskou (M)

Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Institute for Infection, Immunology & Inflammation, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH